Bin‐Yan Zhong

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 262 citations · Full text

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 119 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +9

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

Stephen G. Patterson, Sheng Wei, X Chen et al. · Oncogene · 2006 · 114 citations

Urology, Prostate Tumor Cells, Medicine +7

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study

Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen et al. · European Radiology · 2023 · 75 citations · Full text

Significance of white blood cell count and its subtypes in patients with acute coronary syndrome

Guan‐Hua Huang, Xiaoning Zhong, Bin‐Yan Zhong et al. · European Journal of Clinical Investigation · 2009 · 64 citations